U.S. to pay $2.9 billion for an additional 1.4 million doses of Regeneron's COVID-19 therapyMarket Watch • 09/15/21
Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COV™ (casirivimab and imdevimab) Antibody CocktailPRNewsWire • 09/14/21
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/13/21
Dupixent® (dupilumab) Pivotal Trial Meets All Primary and Secondary Endpoints Becoming First Biologic Medicine to Significantly Reduce Signs and Symptoms of Moderate-to-severe Atopic Dermatitis in Children as Young as 6 MonthsPRNewsWire • 08/30/21
Regeneron Touts Mid-Stage Win For Higher Dose Of Eylea In Age-related Macular DegenerationBenzinga • 08/24/21
Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular DegenerationPRNewsWire • 08/24/21